Novelix Pharmaceuticals Limited (formerly known as Trimurthi Limited) has announced the successful completion of its Extra Ordinary General Meeting (EGM) held on January 09, 2026. The meeting was conducted through video conferencing at 03:30 P.M. IST, with voting results disclosed under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Meeting Participation and Voting Details

The EGM witnessed significant shareholder participation despite being conducted virtually. As of the cutoff date of January 02, 2026, the company had 3,085 total shareholders. The meeting saw attendance from 64 participants through video conferencing, including 3 from the promoter and promoter group category and 61 from the public category.

Resolution Results and Voting Pattern

Both resolutions presented at the EGM received unanimous approval from shareholders. The voting process included remote e-voting prior to the meeting and e-voting during the meeting, with a total of 86 shareholders participating in the electronic voting process.

Resolution 1: Issue of Equity Shares on Preferential Basis (Special Resolution)

Resolution 2: Appointment Confirmation (Ordinary Resolution)

The second resolution concerned the confirmation of Ms. Sridevi Belide (DIN: 10455373) as Additional Director and Non-Executive Non-Independent Director of the company. This resolution also received identical voting results with complete unanimity.

Scrutinizer's Report and Compliance

Bharat Khaniwal & Co., Practicing Company Secretaries, served as the appointed scrutinizer for the e-voting process. Bharat Khaniwal (Membership Number 29035, Certificate of Practice Number 27989) conducted the scrutiny of both remote e-voting and e-voting during the meeting.

The remote e-voting period commenced on January 06, 2026, at 09:00 A.M. IST and concluded on January 08, 2026, at 05:00 P.M. IST. The company utilized the e-voting facility provided by Central Depository Services (India) Limited (CDSL) for the electronic voting process.

Corporate Information and Communication

The voting results have been uploaded in XBRL format on the BSE portal as required under regulatory compliance. Venkateshwarlu Pulluru, Whole-time Director (DIN: 02076871), signed the communication to BSE Limited regarding the voting results.

The company, headquartered in Hyderabad, Telangana, operates under CIN: L67120TG1994PLC018956 with BSE scrip code 536565 and security ID NOVELIX. The successful completion of the EGM with unanimous approval demonstrates strong shareholder confidence in the company's strategic decisions and leadership appointments.

Novelix Pharmaceuticals Limited successfully conducted its Extra Ordinary General Meeting on January 9, 2026, addressing critical corporate governance matters through virtual participation. The meeting, held via video conferencing, demonstrated the company's commitment to maintaining transparent shareholder engagement while adhering to regulatory requirements.

Meeting Structure and Participation

The Extra Ordinary General Meeting commenced at 3:30 PM and concluded at 3:56 PM on January 9, 2026. A total of 64 members attended the meeting through Video Conferencing and Other Audio-Visual Means (OAVM), ensuring adequate representation for the proceedings.

Board and Leadership Attendance

The meeting witnessed comprehensive participation from the company's leadership team. Key attendees included Mr. Gattu Gnana Prakash as Director and Chairman, Mr. Venkateshwarlu Pulluru as Whole-time Director, and several other board members including Independent Director Mr. Janardhan Das Kabra and Director Mr. Jivamohan Divakar Valluri.

Additional participants comprised Ms. Sridevi Belide as Additional Director, Ms. Mayuri Baidya as Director, Ms. Nishita Kalantri as Company Secretary & Compliance Officer, and Ms. Bhoomika Choudhary as Chief Financial Officer. Mr. Bharat Khaniwal served as the appointed Scrutinizer for the voting process.

Key Agenda Items and Resolutions

The meeting focused on two primary business items, both requiring shareholder approval through electronic voting mechanisms. The agenda addressed strategic corporate decisions essential for the company's operational and governance framework.

E-Voting Process and Compliance

Novelix Pharmaceuticals implemented a comprehensive e-voting system to facilitate shareholder participation. The remote e-voting period extended from 9:00 AM on January 6, 2026, to 5:00 PM on January 8, 2026, providing members with adequate time to cast their votes.

The company engaged CDSL to provide the remote e-voting facility, ensuring technical reliability and security. Members who had not participated in remote e-voting were provided with an additional 15-minute e-voting window during the meeting itself. The combined results of both remote e-voting and meeting e-voting will be announced within 48 hours of the meeting's conclusion, with notifications sent to the stock exchange and publication on the company's website at www.novelixpharma.com .

Regulatory Compliance and Documentation

The meeting was conducted in full compliance with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and the Companies Act, 2013. The company maintained proper documentation and notification procedures, ensuring all stakeholders received appropriate information regarding the meeting outcomes and voting results.